iBio, Inc.
NASDAQ:IBIOBiotechnology
+$0.00 today
- Market cap
- $59.75M
- Beta
- 1.29
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.81M
IBIO Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
iBio, Inc.NASDAQ: IBIO
Change in Working Capital · Q4 FY2026 · quarter ended Jun 2026
Change in working capital growth accelerates
Q4 FY2026 change in working capital of $3.65M rose 45550.0% year over year, ahead of the +426.5% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -24.5% a year.
Context
- Change in working capital amounted to 2522.0% of revenue in FY2026, up 2402.2 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +45550.0% holds above the trailing-twelve-month pace of +426.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2026
- 2.52M USD
- Year-over-year change
- +426.5%
- 4-year CAGR
- -6.1%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 2.52M | +426.5% |
| FY2025 | 2025-06-30 | 479K | +115.1% |
| FY2024 | 2024-06-30 | (3.17M) | -154.0% |
| FY2023 | 2023-06-30 | 5.87M | +81.0% |
| FY2022 | 2022-06-30 | 3.24M | — |
Change in Working Capital vs competitors
How IBIO compares with its peers on the latest reported figures
- IBIO's LTM Jun 2026 change in working capital of $2.52M is the largest of the 4 companies compared; the peer median is $1.41M.
- Its year-over-year change of +426.5% is the highest of 4, against a peer median of -27.0%.
- Change in working capital amounts to 2522.0% of revenue for IBIO, versus a peer median of 164.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.52M | +426.5% | -24.5% | 2522.0% | |
| LTM Mar 2026 | $1.68M | -27.0% | -64.7% | — | |
| LTM Mar 2026 | $1.41M | -73.3% | +64.8% | 164.0% | |
| LTM Mar 2026 | $821K | +180.3% | +58.7% | — | |
| Peer median (excluding IBIO) | $1.41M | -27.0% | +58.7% | 164.0% | |
Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | (29.51M) | (65.01M) | (24.91M) | (18.38M) | (33.04M) |
| Depreciation & Amortization | 3.79M | 1.38M | 1.25M | 291K | 88K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.38M | 4.39M | 2.04M | 1.53M | 1.37M |
| Change in Working Capital | 3.24M | 5.87M | (3.17M) | 479K | 2.52M |
| Accounts Receivables | 4.21M | 6.1M | 0 | 0 | (65K) |
| Inventory | (3.87M) | (1.02M) | 0 | 0 | 0 |
| Accounts Payables | 1.24M | (625K) | (1.49M) | 1.83M | 2.22M |
| Other Working Capital | 1.66M | 1.41M | (1.68M) | (1.35M) | 364K |
| Other Non-Cash Items | (15.32M) | 22.93M | 6.23M | 773K | 5.84M |
| Operating Cash Flow | (37.8M) | (30.44M) | (18.55M) | (15.3M) | (23.22M) |
| Capital Expenditures | (7.33M) | (5.74M) | (210K) | (16K) | (578K) |
| Acquisitions (Net) | 0 | (692K) | 0 | 0 | 0 |
| Purchases of Investments | (7.12M) | 0 | 0 | 0 | (42.3M) |
| Sales of Investments | 13.62M | 10.84M | 0 | 0 | 0 |
| Other Investing Activities | (4.3M) | 2.6M | 1.12M | 758K | 10.88M |
| Investing Cash Flow | (5.13M) | 7.01M | 906K | 742K | (32M) |
| Debt Repayment | (5.83M) | (9.13M) | (1.14M) | (771K) | (6.63M) |
| Common Stock Issued | 77K | 11.49M | 25.52M | 9.7M | 109.58M |
| Common Stock Repurchased | 0 | (39K) | (7K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50K) | (22K) | 197K | 0 | 105K |
| Financing Cash Flow | (5.8M) | 2.3M | 24.49M | 8.93M | 103.05M |
| Effect of Forex Changes | (6M) | 33K | 0 | 0 | (18K) |
| Net Change in Cash | (54.73M) | (21.09M) | 6.85M | (5.63M) | 47.83M |
| Free Cash Flow | (45.13M) | (36.17M) | (18.76M) | (15.32M) | (23.8M) |
iBio, Inc.
NASDAQ:IBIO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.